The Group expects to report total revenues for the 12 months ended 31 December 2021 of approximately £315 million, representing growth of over 22% on a constant exchange rate (CER) basis and 17% on a reported basis (12 months to 31 December 2020: £269.3 million). This figure includes a contribution of approximately £2.5 million of incremental revenue1 from BioVision following the acquisition’s completion on 27 October 2021.
Revenue growth continues to be driven by demand for the Company’s proprietary products, with in-house catalogue sales up approximately 37% CER on an organic basis (43% including BioVision), together with a continued recovery in global lab activity. Whilst risks related to the pandemic remain – as evidenced by the emergence of the Omicron variant in late 2021 – data indicates that, while not yet returning to pre-covid levels, overall lab activity continued to increase through 2021.
The Group has continued to build capabilities, invest in innovation and implement its multi-year growth strategy throughout the period. Overall, we anticipate adjusted operating profits will be reported in line with the board’s expectations for the period and we remain on track to achieve our financial goals for the five year plan ending in 2024.
Following the change in the Company’s financial year end to 31 December, full results for the 18 month period ended 31 December 2021 will be released on 14 March 2022. In order to aid comparison, pro forma information for the 12 month periods ended 31 December 2021 and 31 December 2020 will also be provided.
Alan Hirzel, CEO of Abcam commented:
“2021 was a year of significant innovation and growth in proteomic tools and discovery. I thank our customers for trusting Abcam as their preferred partner and our global colleagues for their unwavering dedication to customer needs and aspirations. Together, we are building a durable enterprise that is making a difference in the pace and social impact of discovery. I am confident in our progress toward our 2024 business goals and I look forward to providing the full update in March.”
1 Incremental revenue excludes sales of BioVision products through Abcam channels
This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation.